| Literature DB >> 24825348 |
Brian J North1, Michael A Rosenberg2, Karthik B Jeganathan3, Angela V Hafner1, Shaday Michan1, Jing Dai2, Darren J Baker3, Yana Cen4, Lindsay E Wu5, Anthony A Sauve4, Jan M van Deursen3, Anthony Rosenzweig2, David A Sinclair6.
Abstract
Mice overexpressing the mitotic checkpoint kinase gene BubR1 live longer, whereas mice hypomorphic for BubR1 (BubR1(H/H)) live shorter and show signs of accelerated aging. As wild-type mice age, BubR1 levels decline in many tissues, a process that is proposed to underlie normal aging and age-related diseases. Understanding why BubR1 declines with age and how to slow this process is therefore of considerable interest. The sirtuins (SIRT1-7) are a family of NAD(+)-dependent deacetylases that can delay age-related diseases. Here, we show that the loss of BubR1 levels with age is due to a decline in NAD(+) and the ability of SIRT2 to maintain lysine-668 of BubR1 in a deacetylated state, which is counteracted by the acetyltransferase CBP. Overexpression of SIRT2 or treatment of mice with the NAD(+) precursor nicotinamide mononucleotide (NMN) increases BubR1 abundance in vivo. Overexpression of SIRT2 in BubR1(H/H) animals increases median lifespan, with a greater effect in male mice. Together, these data indicate that further exploration of the potential of SIRT2 and NAD(+) to delay diseases of aging in mammals is warranted.Entities:
Keywords: BubR1; NADzzm321990+; acetylation; aging; sirtuin
Mesh:
Substances:
Year: 2014 PMID: 24825348 PMCID: PMC4194088 DOI: 10.15252/embj.201386907
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598